Entry level $118 = Target price $137 = Stop loss $115
Bullish price action on the breakout.
OBV indicator very strong as is the RSI
Volume dominated by buyers.
Short interest can still furl the rally at 14%
Company profile
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Bullish price action on the breakout.
OBV indicator very strong as is the RSI
Volume dominated by buyers.
Short interest can still furl the rally at 14%
Company profile
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.